Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer

A recent study looked at the efficacy and safety of first-line treatment with a combination of immunotherapies (immune checkpoint inhibitors) for sarcomatoid renal cell carcinoma (RCC). The analysis included five clinical trials involving 568 patients with sarcomatoid RCC. All combinations that were looked at significantly improved progression-free survival and response rate. Combination treatments with nivolumab […]

read more

ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery

Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number of cancer cells (tumour burden), reduce the symptoms and immunosuppression caused by the tumour, and prevent complications. Recent studies have questioned the role of cytoreductive nephrectomy for patients with RCC that has spread (metastatic RCC). Metastatic sarcomatoid/rhabdoid clear cell RCC is an aggressive type of RCC that responds […]

read more

Cabozantinib in pretreated patients with sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This real […]

read more

ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer

The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus the VEGF inhibitor, axitinib for advanced renal cell carcinoma continues to show survival benefits compared with sunitinib as a first treatment after surgery. In this oral presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting, further follow-up data from KEYNOTE-426 over more than […]

read more

ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are stopped from getting to the brain by a membrane called the blood-brain barrier. Most patients with brain metastases have, therefore, been excluded from phase 3 clinical trials. In the phase 3/4 CheckMate 920 study, presented at […]

read more

Immune checkpoint inhibitors for sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the tumour cells look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to targeted […]

read more

Top stories from 2020 for kidney cancer

Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the Kidney Cancer Programme, at the City of Hope Hospital, California talks about the changes in the management of renal cell carcinoma (RCC) over the past decade. He talks about combination treatments such as nivolumab with ipilimumab, which shows the potential for a complete response in […]

read more

2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

Immunotherapy for the treatment of metastatic sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This study […]

read more

First-line treatment of patients with sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, […]

read more
Showing 1 to 10 of 26 results
  TOP